CalciMedica Inc - מכפיל EV/Sales CALI

The change in the EV/Sales multiple demonstrates the dynamics of CalciMedica, Inc. (CALI), which develops unique CRAC channel inhibitors for the therapy of pancreatitis. The current R&D pipeline is focused on collecting data on inflammatory pathologies, while 0.00 is recorded as the baseline value. Business resilience is ensured by advancing drugs through clinical trial stages at US research sites.
CALI (CalciMedica): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator compares the total enterprise value, adjusted for net debt, against the volume of generated revenue to determine the asset's fundamental attractiveness. An EV/Sales valuation analysis allows for the filtering of market noise and confirms the resilience of CalciMedica, Inc. (CALI), whose capitalization relies on the long-term potential of patent protection for innovative drugs used in the therapy of severe inflammatory processes.